Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (‘GLP-1’) agonist research program. GLP-1, a class of drugs, has demonstrated an ability to significantly address diabetes and obesity. What Lexaria’s unique drug delivery platform offers is the added ability to greatly improve the otherwise poor oral bioavailability of GLP-1 drugs, making it possible for simple oral application versus traditional injection, an opportunity of huge implication in the marketplace.”
To view the full article, visit https://ibn.fm/ti0Hs
About Lexaria Bioscience Corp.
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
[email protected]
TinyGems is powered by IBN